Biogen begins construction of its Danish powerbase  

Today marks the official start of building work on Biogen's new production plant in Medicon Valley

The biotech company Biogen Manufacturing is today lifting the first spit to mark the official start of the group’s first production facility outside the US. The new plant is being built in Hillerød north of Copenhagen, part of Medicon Valley, and will become one of the world’s largest biotechnological factories. The first phase includes a 34,000 sq m building housing the production plant itself, two buildings for supplementary functions (power plant, process water and storage) and a separate three storey building housing laboratories and administration. The news is reported by financial daily newspaper Børsen.


The new plant will produce products for the European market as well as serving in a backup capacity for the US market. As reported previously on this website, Biogen has said that its multiple sclerosis treatment Avonex (Interferon beta 1a) will be the first product put into production, although the facility's principal role will be to produce Amevive (alefacept), a protein-based drug for the treatment of patients with moderate-to-severe psoriasis. Biogen also has a pipeline drug called Antegren for Crohn's disease.


The cost of the first building phase at the Hillerød site is estimated at DKK 1.7 billion (USD 243 million). Estimates of the total investment for the whole project have been put at around DKK 3 billion (USD 430 million). The first spit will be lifted today by Minister for Science, Technology and Innovation Helge Sander, assisted by the Mayor of Hillerød and Biogen’s Danish Director Poul Coleman. Biogen has its headquarters in Cambridge Mass. and employs approximately 2,700 people worldwide. In 2002 the company’s turnover was almost DKK 8 billion (USD 1.1 billion).

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×